Table 2.
Published year | Coverage | Research objective | Grouping design | Sample source | Sample type | Analytic method | Reference |
---|---|---|---|---|---|---|---|
2013 | Untargeted | Pathogenesis | ICP vs Control | Human body | Placenta | iTRAQ LC-MS/MS | (27) |
2014 | Untargeted | Pathogenesis | ICP vs Control | Human body | Placenta | 2D-PAGE MS | (28) |
2019 | Untargeted | Pathogenesis | Taurocholate vs Control (in vitro cultured tissue model) | In vitro tissue | Placenta | iTRAQ LC-MS/MS | (29) |
2019 | Targeted | Pathogenesis | ICP vs Control | Human body | Placenta | Immunohistochemistry | (30) |
2021 | Untargeted | Diagnosis | ICP vs Control | Human body | Serum | DIA LC-MS/MS | (31) |
2022 | Untargeted | Pathogenesis | ICP vs Control | Human body | Placenta | DIA LC-MS/MS | (32) |
2022 | Untargeted | Pathogenesis | Chenodeoxycholic acid vs Deoxycholic acid vs Control | Cell line | HTR8 cells | TMT LC-MS/MS | (33) |
2023 | Untargeted | Pathogenesis | mild ICP vs severe ICP vs Control | Human body | Placenta | DIA LC-MS/MS | (34) |
2023 | Untargeted | Diagnosis | ICP vs Control | Human body | Plasma exosomes | DIA LC-MS/MS | (35) |